SomaLogic has collaborated with Illumina to co-develop next-generation sequencing (NGS)-based proteomic solutions.
Under the multi-year partnership deal, the companies will bring genomics and proteomics technology platforms together to enable proteomics and multi-omics research across the world.
Illumina will be responsible for the development and deployment of NGS-based protein identification and measurement tools in laboratories globally.
The company will also enable the use and development of high-plex protein pattern recognition tests.
Additionally, Illumina will commence a development effort for integrating the protein target volume of SomaLogic with its informatics toolsets, sequencing technologies and DRAGEN software.
This will enable the creation of a complete workflow solution for NGS.
SomaLogic CEO Roy Smythe said: “This is truly a transformational partnership that will democratise and accelerate our understanding of the human proteome.
“It definitively signals that the era of proteomics is here and that SomaLogic, and now Illumina, will lead that era.
“The combined capabilities of our two companies – the scientific and commercial leaders in both next-generation genomic sequencing and proteomics – will inevitably have a profound impact on the understanding, avoidance and treatment of human disease.”
Additionally, the companies will use the global commercial infrastructure of Illumina and the unique proteomics platform of SomaLogic.
SomaLogic stated that it can measure and detect 7,000 human proteins on a single 55 microliter plasma or serum sample.
The company intends to expand its reagents and assay to run 10,000 protein measurements over the next year.
Last September, Illumina and Merck (MSD) collaborated to develop and market companion diagnostic (CDx) and research tests to identify specific cancer mutations.